Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCOMG5)

• Drug Name: AZD-1744 Drug Info
• Synonyms: Dual CCR3/H-1 receptor antagonist (chronic obstructive pulmonary disease (COPD)), AstraZeneca

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Discontinued in Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMCOMG5

Molecule-Related Drug Atlas

Drug(s) Targeting C-C chemokine receptor type 3 (CCR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AKST4290	DM27ZJG	Parkinson disease	8A00.0	Phase 2	[3]
DPC-168	DMA7DH0	Allergic rhinitis	CA08.0	Discontinued in Phase 1	[4]
YM-344031	DMMUYC2	Asthma	CA23	Preclinical	[5]
YM-355179	DMTM1LK	Asthma	CA23	Preclinical	[5]
QAP-642	DM8RHST	Allergic rhinitis	CA08.0	Terminated	[6]

Drug(s) Targeting Histamine H1 receptor (H1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[7]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[8]
Azelastine	DMXTMBJ	Allergic conjunctivitis	9A60.02	Approved	[9]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[10]
Cinnarizine	DM7U5QJ	Meniere disease	AB31.0	Approved	[11]
Diphenhydramine	DMKQTBA	Hyperemesis gravidarum		Approved	[9]
Doxepin	DMPI98T	Anxiety		Approved	[12]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[9]
Epinastine	DMX0K3Q	Allergic conjunctivitis	9A60.02	Approved	[13]
Desloratadine	DM56YN7	Allergic rhinitis	CA08.0	Approved	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 3 (CCR3)	TTD3XFU	CCR3_HUMAN	Modulator	[2]
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025772)
• [2] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [3] SAFETY AND THERAPEUTIC EFFECTS OF ORALLY ADMINISTERED AKST4290 IN NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2022 Jun 1;42(6):1038-1046.
• [4] CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2992-7.
• [5] Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53.
• [6] New Drugs and Targets for Asthma and COPD. T.T. Hansel, P.J. Barnes. 2010. Page 158.
• [7] Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
• [8] Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
• [9] Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
• [10] Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
• [11] Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
• [12] Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
• [13] Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
• [14] Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.